Abstract
Programmed cell death-1 (PD-1, Pdcd1), an immunoreceptor belonging to the CD28/CTLA-4 family negatively regulates antigen receptor signaling by recruiting protein tyrosine phosphatase, SHP-2 upon interacting with either of two ligands, PD-L1 or PD-L2. Because of the wide range of ligand distribution in the body, its biological significance pervades almost every aspect of immune responses including autoimmunity, tumor immunity, infectious immunity, transplantation immunity, allergy and immunological privilege. In this review, we would like to summarize the history of PD-1 research since its discovery and recent findings that suggest promising future for the clinical application of PD-1 agonists and antagonists to various human diseases.
Keywords
AutoimmunityImmunityImmunologyBiologyImmune system
Affiliated Institutions
Related Publications
SHP-1 and SHP-2 Associate with Immunoreceptor Tyrosine-Based Switch Motif of Programmed Death 1 upon Primary Human T Cell Stimulation, but Only Receptor Ligation Prevents T Cell Activation
Abstract To study the cis- and trans-acting factors that mediate programmed death 1 (PD-1) signaling in primary human CD4 T cells, we constructed a chimeric molecule consisting ...
THE B7 FAMILY REVISITED
▪ Abstract The discovery of new functions for the original B7 family members, together with the identification of additional B7 and CD28 family members, have revealed new ways i...
The PD‐1 pathway in tolerance and autoimmunity
Summary: Regulatory T cells (Tregs) and the PD‐1: PD‐ligand (PD‐L) pathway are both critical to terminating immune responses. Elimination of either can result in the breakdown o...
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
Vaccination with irradiated B16 melanoma cells expressing either GM-CSF (Gvax) or Flt3-ligand (Fvax) combined with antibody blockade of the negative T-cell costimulatory recepto...
Coinhibitory Pathways in Immunotherapy for Cancer
The immune system is capable of recognizing tumors and eliminates many early malignant cells. However, tumors evolve to evade immune attack, and the tumor microenvironment is im...
Publication Info
- Year
- 2007
- Type
- review
- Volume
- 19
- Issue
- 7
- Pages
- 813-824
- Citations
- 1257
- Access
- Closed
External Links
Social Impact
Altmetric
PlumX Metrics
Social media, news, blog, policy document mentions
Citation Metrics
1257
OpenAlex
Cite This
Taku Okazaki,
T Honjo
(2007).
PD-1 and PD-1 ligands: from discovery to clinical application.
International Immunology
, 19
(7)
, 813-824.
https://doi.org/10.1093/intimm/dxm057
Identifiers
- DOI
- 10.1093/intimm/dxm057